Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10262847
• 负责人: SUZANNE CRAFT
• 金额: $ 304.61万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10262847
• 关键词: Address; Adult; African American; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease risk; American; Amyloid; Area; Biological Markers; Blood Vessels; Capsicum; Clinical; Clinical Sciences; Clinical Trials; Cognition; Collaborations; Communities; Complex; Data; Dementia; Diabetes Mellitus; Disease; Doctor of Philosophy; Early Intervention; Ecosystem; Education; Elderly; Enrollment; Ensure; Epidemic; Faculty; Faculty Recruitment; Family; Family health status; Foundations; Functional disorder; Funding; General Population; Goals; Grant; Health Professional; Heterogeneity; High Prevalence; Human; Hypertension; Impaired cognition; Infrastructure; Institutes; Intervention Trial; Leadership; Magnetic Resonance Imaging; Medical; Metabolic; Metabolic Diseases; Methods; Mission; Modeling; Neurosciences; Participant; Patient Education; Patients; Phase Transition; Play; Positron-Emission Tomography; Prediabetes syndrome; Predictive Factor; Prevalence; Prevention; Prevention strategy; Publications; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Statistical Data Interpretation; Strategic Planning; Symptoms; Training; Translational Research; Underrepresented Populations; Vascular Diseases; Work; behavioral neurology; clinical center; clinical implementation; cohort; data management; disease heterogeneity; education research; experience; forest; health disparity; health equity; imaging biomarker; innovation; investigator training; medical schools; neuroimaging; neuropathology; nonhuman primate; normal aging; novel; novel strategies; outreach; prevent; preventive intervention; programs; recruit; repository; resilience; symptom treatment; tau Proteins; translational pipeline; vascular factor; vascular risk factor

Overall – Project Summary The Alzheimer’s Disease Research Center (ADRC) was founded at Wake Forest School of Medicine (WFSM) in 2016 to provide a comprehensive infrastructure for research on the pathophysiology, prevention, and treatment of AD and related disorders (ADRD). The theme of our ADRC is to better understand early transitions from normal aging to MCI and dementia, and to elucidate the role that metabolic and vascular factors play in these transitions, through coordinated research activities spanning the translational spectrum. No current therapies effectively prevent or treat the symptoms of AD. This chasm highlights the need to identify antecedent biomarkers and risk factors that predict later-life vulnerability or resilience, in order to develop strategies for prevention and early intervention. Metabolic and vascular disorders are powerful modifiable factors that may contribute to the transitions from normal aging to MCI and ADRD. Such disorders are epidemic in the Southeastern region surrounding the WF ADRC; more than 70% of adults over the age of 50 have prediabetes, diabetes, or hypertension. These disorders increase the risk of cognitive impairment and dementia through complex interactions that are poorly understood. The WF ADRC seeks to provide resources to better understand these interactions. We also seek to elucidate the multi-dimensional role that health disparities play in influencing risk for AD. We emphasize engagement of African Americans and other underrepresented groups, who are twice as likely to develop dementia, and have high rates of diabetes and vascular disease. To promote innovative research on metabolic/vascular risk and health disparities, our Outreach, Recruitment and Engagement and Clinical Cores have partnered to enroll and follow ~600 participants, carefully characterizing their vascular and glycemic status. Participants receive magnetic resonance imaging and amyloid and tau positron emission tomography overseen by the Imaging Biomarker Core. Valuable samples and data from this cohort are made widely available to the National Alzheimer’s Coordinating Center, the National Centralized Repository for AD and other investigators by the Data Management and Statistical Analysis and Neuropathology Cores, providing invaluable resources to address numerous National Alzheimer’s Project Act milestones. The Neuropathology Core has also characterized novel nonhuman primate models with methods that parallel the ADRC’s human cohort to promote translational research. Finally, the ADRC and its Research Education Component provide training relating to AD, metabolic/ vascular factors and health disparities to a diverse cadre of new researchers, and education for patients and families, health professionals, and the community. The prevalence of metabolic and vascular risk factors, their role in onset, progression, and heterogeneity of ADRDs, and the strengths of the WF ADRC in these research areas, ensure that we will make high-impact contributions to the search for strategies to treat and prevent AD.

总体-项目摘要 阿尔茨海默病研究中心（ADRC）成立于维克森林医学院（WFSM） 在2016年提供一个全面的基础设施研究的病理生理学，预防， 治疗AD和相关疾病（ADRD）。我们ADRC的主题是更好地了解早期 从正常衰老到MCI和痴呆的转变，并阐明代谢和血管 通过跨越翻译范围的协调研究活动，这些因素在这些转变中发挥作用。 目前没有有效预防或治疗AD症状的疗法。这一鸿沟突出表明， 预测晚年脆弱性或复原力的先行生物标志物和风险因素， 预防和早期干预战略。代谢和血管疾病是可以改变的 可能导致从正常衰老向MCI和ADRD转变的因素。这样的疾病 在WF ADRC周围的东南部地区流行;超过70%的50岁以上的成年人 有前驱糖尿病、糖尿病或高血压。这些疾病会增加认知障碍的风险， 痴呆症通过复杂的相互作用，这是知之甚少。WF ADRC寻求提供资源， 来更好地理解这些相互作用。我们还试图阐明健康在促进人类健康方面的多层面作用， 差异在影响AD风险方面发挥作用。我们强调非裔美国人和其他 代表性不足的群体，他们患痴呆症的可能性是其他群体的两倍，糖尿病的发病率很高， 血管疾病为了促进对代谢/血管风险和健康差异的创新研究，我们 外联、招募和参与以及临床核心已合作招募并跟踪约600名 参与者，仔细描述他们的血管和血糖状态。参与者收到磁 共振成像和淀粉样蛋白和tau正电子发射断层扫描，由成像生物标志物监督 核心来自这一队列的有价值的样本和数据被广泛提供给国家阿尔茨海默氏症研究中心。 协调中心，国家AD集中存储库和其他研究者的数据 管理和统计分析以及神经病理学核心，为解决 国家老年痴呆症项目法案的众多里程碑。神经病理学核心也具有新颖的特点 非人灵长类动物模型与方法，平行ADRC的人类队列，以促进翻译 research.最后，ADRC及其研究教育部分提供与AD、代谢/代谢相关的培训。 血管因素和健康差异的新的研究人员，并为患者和教育的多样化干部， 家庭、卫生专业人员和社区。代谢和血管危险因素的患病率， 在ADRD的发生、进展和异质性中的作用，以及WF ADRC在这些研究中的优势 在这些领域，确保我们将为寻求治疗和预防AD的策略做出具有高度影响力的贡献。